Hybridoma-producing NSO myeloma cell line |
| This invention is directed to NSO.sup.bcl-2 myeloma cells and to methods of producing said cells. T... |
|
Bax inhibitor proteins |
| The present invention provides substantially purified nucleic acid molecules encoding Bax inhibitor ... |
|
Phosphonomonoester nucleic acids, process for their preparation, and their use |
| What is claimed is: 1. A compound of formula I ##STR37## in which n is a number from zero to 100; A ... |
|
Oligonucleotide phosphate esters |
| OF THE PREFERRED EMBODIMENTS The present invention provides oligonucleotide analogs characterized ... |
|
Liposomes containing oligonucleotides |
| What we claim is: 1. A composition comprising cationic liposomes which consist essentially of ... |
|
Protonated/acidified nucleic acids and methods of use |
| OF THE PREFERRED EMBODIMENTS It is to be understood that this invention is not limited to the ... |
|
Oligonucleotide derivatives |
| What is claimed is: 1. A compound which is selected from the group consisting of the base ... |
|
Crystal forms of azithromycin |
| The present invention relates to crystal forms of azithromycin. As used herein, the term "crystal ... |
|
Method for delivering melanin to hair follicles |
| It has now been discovered that liposomes can selectively target the hair follicle with potentially ... |
|
|
Highly packed polycationic ammonium, sulfonium and phosphonium lipids
| Details |
Inventors: Haces, Alberto; Ciccarone, Valentina C.;
Assignee: Life Technologies, Inc. (Rockville, MD)
Primary Examiner: Raymond; Richard L.
Assistant Examiner:
Attorney, Agent or Firm: Greenlee, Winner and Sullivan, P.C.
The present invention discloses highly packed polycationic ammonium, sulfonium and phosphonium lipid compounds useful for making lipid aggregates for delivery of macromolecules and other compounds into cells. They are especially useful for the DNA-dependent transformation of cells. Methods for their preparation and use as intracellular delivery agents are also disclosed. |
|
DETAILED DESCRIPTION OF THE INVENTION The present invention provides novel, highly packed polycationic ammonium, sulfonium and phosphonium lipid compounds having unique properties and advantages not heretofore available to the liposome art. The compounds can be used alone or in combination with other compounds (e. g. , DOPE, DOTMA and DOSPA) to prepare liposomes and other lipid aggregates suitable for transfection or delivery of compounds other than DNA to target cells, either in vitro or in vivo. The novel compounds of general formula (I) are polycationic and thus form highly stable complexes with various anionic macromolecules, particularly polyanions such as nucleic acids. These compounds have the property, when dispersed in water, of forming lipid aggregates which associate strongly, via their cationic portions, with polyanions. By using an excess of cationic charges relative to the anionic compound, the polyanion-lipid complexes may be adsorbed on cell membranes, thereby facilitating uptake of the desired compound by the cells. The cationic lipids disclosed herein offer three unique advantages over prior art compounds. First, the compounds of general formula (I) represent novel liposomal precursors wherein the polycationic binding regions are optimally spaced, preferably equidistance between charges, to provide proper alignment with the anionic phosphates of nucleic acids. Proper alignment of charges increases the binding constant of the lipid to nucleic acid via cooperative interaction. This increased affinity produces a more stable DNA-lipid complex, which in turn increases the efficiency of delivery. Thus, lower concentrations of these agents are required to coat the molecules and bind to the target cells, thereby maximizing efficiency of delivery while minimizing cell toxicity. The second unique advantage of the compounds disclosed herein is their unusually high affinity for the lipid bilayer of cell membranes. Unlike the mono-substituted lipopolyamine compounds currently in use, the compounds of the invention comprise lipidic substituents at each cationic binding region
|
|